The Case Transgenic &Targeting Core Facility is the sole service generating genetically modified mice for the Case Comprehensive Cancer Center (Case CCC) and the Cleveland Biomedical community. The facility makes transgenic and gene-targeted mice, in addition to performing rederivations, in vitro fertilization, cryopreservation, and other services. The facility has a staff of four and a director. The service has a laboratory suite of about 1700 square feet adjacent to a state-of-the-art animal facility, and is equipped with four microinjection stations, two tissue culture hoods, and three surgery hoods. The facility operates on a fee-for-service basis, and provides consultation with all services. The facility supports the Case Comprehensive Cancer Center mission through the generation of mouse models of cancer, and tools and materials for investigation of basic science questions. The facility has not received support from the Case CCC previously. Case CCC members accounted for 42% of the use of the facility in 2004 and 2005. Support from the Case CCC would be used to hire an additional staff member to ensure that service backlogs do not occur. In addition, Case CCC members would benefit from discounted fees for services, at less than the academic average.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-21
Application #
8103093
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
21
Fiscal Year
2010
Total Cost
$114,711
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Liu, Xia; Taftaf, Rokana; Kawaguchi, Madoka et al. (2018) Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. Cancer Discov :
Belur Nagaraj, Anil; Joseph, Peronne; Kovalenko, Olga et al. (2018) Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer. Gynecol Oncol 151:525-532
Li, Jiayang; Gresham, Kenneth S; Mamidi, Ranganath et al. (2018) Sarcomere-based genetic enhancement of systolic cardiac function in a murine model of dilated cardiomyopathy. Int J Cardiol 273:168-176
Enane, Francis O; Saunthararajah, Yogen; Korc, Murray (2018) Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis 9:912
Lennon, Donald; Solchaga, Luis A; Somoza, Rodrigo A et al. (2018) Human and Rat Bone Marrow-Derived Mesenchymal Stem Cells Differ in Their Response to Fibroblast Growth Factor and Platelet-Derived Growth Factor. Tissue Eng Part A 24:1831-1843
Evans, Daniel R; Venkitachalam, Srividya; Revoredo, Leslie et al. (2018) Evidence for GALNT12 as a moderate penetrance gene for colorectal cancer. Hum Mutat 39:1092-1101
Augestad, Knut M; Keller, Deborah S; Bakaki, Paul M et al. (2018) The impact of rectal cancer tumor height on recurrence rates and metastatic location: A competing risk analysis of a national database. Cancer Epidemiol 53:56-64
Chen, Lechuang; Feng, Zhimin; Yue, Hong et al. (2018) Exosomes derived from HIV-1-infected cells promote growth and progression of cancer via HIV TAR RNA. Nat Commun 9:4585
Patel, Rutulkumar; Zhang, Luchang; Desai, Amar et al. (2018) Mlh1 deficiency increases the risk of hematopoietic malignancy after simulated space radiation exposure. Leukemia :
Lager, Angela M; Corradin, Olivia G; Cregg, Jared M et al. (2018) Rapid functional genetics of the oligodendrocyte lineage using pluripotent stem cells. Nat Commun 9:3708

Showing the most recent 10 out of 1227 publications